1 / 34

Targeting Obesity for Endometrial Cancer Treatment

Targeting Obesity for Endometrial Cancer Treatment. Victoria Bae-Jump, MD, PhD Associate Professor Division of Gynecologic Oncology University of North Carolina at Chapel Hill. Disclosure – Novatarg, Merck. Endometrial Cancer and Obesity. 4 th most common cancer among women in the U.S.

robertrbrown
Download Presentation

Targeting Obesity for Endometrial Cancer Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Targeting Obesity for Endometrial Cancer Treatment Victoria Bae-Jump, MD, PhD Associate Professor Division of Gynecologic Oncology University of North Carolina at Chapel Hill

  2. Disclosure – Novatarg, Merck

  3. Endometrial Cancer and Obesity 4th most common cancer among women in the U.S. Obesity, diabetes and insulin resistance are well-known risk factors Each increase in BMI of 5 kg/m2 significantly increases a woman’s risk of developing endometrial cancer.1 Obese women with endometrial cancer have up to a 6.25 increased risk of death.2 1Renehan et. al., Lancet, 371: 569-578 (2008). 2Calle et. al., N Engl J Med, 348: 1625-38 (2003). 1/3/2020 3

  4. Obesity and Endometrial Cancer

  5. Hypothesis • The metabolic consequences of obesity may be crucial in endometrial cancer pathogenesis. • Biologically and metabolically distinct cancers than those that arise in a non-obese environment. • Obesity-driven endometrial cancers may have unique vulnerabilities that could be targeted for treatment. • Metformin • Biguanide • Pre-clinical/epidemiologic studies suggest anti-tumorigenic effects

  6. Metformin’s Anti-tumorigenic Effects • Indirect – improvement in insulin resistance, decrease in circulating insulin and glucose levels • Direct – inhibits mitochondrial complex 1, AMPK activation, leading to inhibition of mTOR pathway, inhibition of lipid and fatty acid synthesis

  7. Metformin and Endometrial Cancer Mouse Model Palpable 1 cm tumor 3 weeks 6 weeks LKB1fl/flp53fl/fl mouse model of endometrioid endometrial cancer Obese (High fat diet) versus Lean (Low fat diet) Metformin versus Placebo

  8. p=0.033 RESULTS p=0.04

  9. Metabolomics: Obese vs Lean Tumors • Striking differences between obese and lean tumors • 251 up- or down-regulated metabolites • Aggressive phenotype of endometrial cancer in obese mice accompanied by alterations in metabolism • Upregulation of lipid biosynthesis • Upregulation of energy metabolism • Upregulation of protein biosynthesis INCREASE DECREASE

  10. ↑ lipid biosynthesis ↑ apo-lipoproteins – increased lipid transport ↑ lipases – release free fatty acids Proteomics: Obese vs Lean Tumors * *p< 0.05

  11. Proteomics: Obese vs Lean Tumors * ↑ protein biosynthesis ↑ proteases – increased protein degradation to provide amino acids ↑ ribosomal subunits and ribosomal stabilizing proteins – increased protein biosynthetic capacity *p< 0.05

  12. Obesity-Driven Alterations in Endometrial Cancer

  13. Obesity and Metformin in LKB1/p53 Mice • Metformin inhibited tumor size/volume in both the obese and lean mice. • Metformin-induced decreases in tumor size/volume in obese mice were significantly greater than in the lean mice (85% versus 61%, respectively, p=0.033). • Metformin’s anti-tumorigenic efficacy may be dependent on obese/insulin resistant states.

  14. Metabolomics - Metformin • Metformin treatment reversed detrimental effects of obesity • Decreased lipid biosynthesis • Increased 3-hydroxybutyrate • Fatty acids and lipids being degraded • Decreased protein turn-over and biosynthesis INCREASE DECREASE

  15. ↑ proteins involved in lipid oxidation/degradation ↑ Lipid-oxidation enzymes ↑ Peroxisome proliferator-activated receptor (PPAR) responsive proteins Proteomics- Metformin in Obese * all p-values significant

  16. ↑ proteins involved in beta-oxidation ↑ proteins involved in fatty acid degradation Excess free fatty acids shunted to beta-oxidation as opposed to lipid biosynthesis Proteomics- Metformin in Obese * all p-values significant

  17. Effect of Metformin on Obesity-Driven Alterations

  18. Preoperative Window Study – Metformin and Endometrial Cancer (UNC) • 20 patients enrolled1 • Endometrioid Histology • BMI > or = 30 • Metformin 850 mg QD • Mean of 14.7 days of treatment, stopped 24 hours prior to hysterectomy/BSO and surgical staging • Ki-67 staining decreased significantly with metformin treatment (mean of 21.9%, signed rank test, p=0.008). • Inhibited targets of the mTOR pathway. 1 1Schuler, KM, Rambally, BS, Difurio, MJ, Sampey, BP, Gehrig, PA, Makowski, L and Bae-Jump, VL. Anti-proliferative and metabolic effects of metformin in a pre-operative window clinical trial for endometrial cancer, Cancer Medicine, 4(2), 161-73 (2016).

  19. A B Metformin inhibited cell proliferation in EC patients. Obese EC patients (n=20) underwent short-term metformin treatment (mean of 14.7 days) in a pre-operative window study. Percent Ki-67 staining, a marker of cell proliferation, decreased significantly with metformin treatment (mean decrease of 21.9%, p=0.008). Endometrium (A) pre-treatment and (B) post-treatment in a patient that responded to metformin treatment, as shown by a decrease in Ki-67 staining.

  20. All early stage, G1-3 • 3 G1 toxicities – mild abdominal pain, loose stools, flatulence • No difference in age, BMI, HgBA1C, stage, grade, or number of days on treatment between responders and non-responders. • Glucose levels decreased in responders and non-responders to metformin but were only statistically significant in responders (p=0.007).

  21. Predictors of Response • Determine any molecular or metabolic biomarkers that could predict response to metformin treatment • Compare responders to non-responders • Immunohistochemical analysis • AMPK, mTOR and insulin pathway derivatives • Metformin transporters • Metabolomic profiling • Baseline and change pre- to post-treatment

  22. Molecular differences in Responders versus Non-Responders • Baseline MATE2 expression approached significance in predicting response to metformin (p=0.0625)

  23. Global Biochemical Serum Profiles • Metformin treatment significantly altered the serum concentrations of 173 metabolites (37 up and 136 down). • 114 metabolites in responders and 67 metabolites in non-responders. • Responders to metformin had seemed to be more sensitive to metformin’s beneficial effects on: • Lipid metabolism • Amino acid metabolism • Gut microbiome-associated metabolites lipid metabolites amino acid metabolites gut microbial metabolites

  24. Baseline Metabolic Differences in Serum Between Responders and Non-responders to Metformin Treatment Higher pre-metformin treatment levels of amino acids, dipeptides, glycolytic intermediates, arachidonic acid, monohydroxy fatty acids and lysolipids in responders when compared to non-responders (p<0.05).

  25. Parallels Between Mouse and Human Data Mouse Endometrial Tumors Human Endometrial Tumors • Metformin inhibited fatty acid synthesis in both human and mouse endometrial tumors. • More pronounced in obese vs lean mice. • More pronounced in responders vs non-responders.

  26. Open Clinical Trials of Metformin in Endometrial Hyperplasia with Atypia/Cancer

  27. Open Clinical Trials of Metformin in Endometrial Hyperplasia/Cancer

  28. GOG 286B:A randomized phase II/III study of paclitaxel/carboplatin/METFORMIN VERSUS paclitaxel/carboplatin/PLACEBO as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer Paclitaxel 175 mg/m2 over 3 hr day 1 Carboplatin AUC 5 day 1q3w + Placebo Advanced and Recurrent Endometrial Cancer (n=540 patients) R Paclitaxel 175 mg/m2 over 3 hr day 1 Carboplatin AUC 5 day 1q3w Metformin 850 mg po BID PI: Victoria Bae-Jump Clinical Primary Endpoints: Progression free survival for the phase II. Overall survival for the phase III. Re-open to Phase 3 in December 2016.

  29. GOG 286B: A randomized phase II/III study of paclitaxel/carboplatin/METFORMIN VERSUS paclitaxel/carboplatin/PLACEBO as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer (NCT02065687) • Outcomes – Clinical: Secondary Endpoints • To estimate the proportion of patients with objective response rate (RR) in the population of patients with measurable disease by treatment. • To estimate the duration of response in the population of patients with measurable disease who respond by treatment. • To estimate overall survival (OS) and relative hazards of death for each treatment arm if the study stops after the phase II trial is completed. If the study continues with a phase III clinical trial, then PFS will be a secondary endpoint. • To determine the nature, frequency and degree of toxicity as assessed by CTCAE for each treatment arm. • To estimate possible differences in RR, PFS, OS, and toxicity rates for the treatment regimens by the patients’ level of obesity.

  30. GOG 286B: A randomized phase II/III study of paclitaxel/carboplatin/METFORMIN VERSUS paclitaxel/carboplatin/PLACEBO as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer (NCT02065687) • Outcomes – Biomarker Endpoints • To explore the association of metabolic factors (BMI, hip-to-waist ratio, diabetes status, HgBA1C, fasting insulin and glucose levels, HOMA scores) with treatment response to metformin/paclitaxel/carboplatin. • Metabolomic profiling • To correlate expression of the metformin transporter proteins (i.e. OCT 1-3, MATE 1/2 and PMAT) and key targets of the metformin/insulin/mTOR signaling pathway with treatment response to metformin/paclitaxel/carboplatin. • Immunohistochemical analysis: Transporter proteins, insulin and mTOR pathway targets • Next generation sequencing: PTEN mutations, PIK3CA mutations/amplifications and PIK3R1/PIK3R2 mutations • Next generation sequencing: Genetic variants of transporter proteins.

  31. GOG 286B: A randomized phase II/III study of paclitaxel/carboplatin/METFORMIN VERSUS paclitaxel/carboplatin/PLACEBO as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer (NCT02065687) • Outcomes – Patient Reported Outcomes Endpoints • To estimate differences in physical functioning, physical activity, and fatigue between treatment arms. • To explore the association between metabolic factors (i.e., BMI, hip-to-waist ratio, diabetes status, HgbA1C, fasting insulin and glucose levels, HOMA scores), physical functioning, physical activity, and fatigue. • Physical Function – Physical Function subscale of SF-36 • Fatigue – Functional Assessment of Chronic Illness-Therapy Scale (FACIT-F ) • Physical Activity – Short form of the International Physical Activity Questionnaire (IPAQ) • Patients will complete the questionnaires at 4 times (0, 6, 15 and 26 weeks).

  32. Conclusions • Endometrial tumors arising in the setting of obesity are metabolically different than their lean counterparts – may have different targets for treatment. • Pre-clinical data suggests that metformin have efficacy in obesity-driven endometrial cancer - multiple clinical trials are in progress. • Other pharmacologic interventions – novel biguanides, statins, phenformin, orlistat, cox-2 inhibitors….

  33. Thank you! • Grant Support (past and present): • NIH/NCI K23 Mentored Patient-Oriented Research Career Development Award Grant • American Gynecological & Obstetrical Society Bridge Grant • Gynecologic Cancer Foundation/Florence & Marshall Schwid Ovarian Cancer Research Grant • NC TraCS $50K Pilot Grant Program • UNC Nutrition Obesity Research Center, Pilot and Feasibility Research Grant • V Foundation Grant • Marsha Rivkin Center for Ovarian Cancer Research Pilot Project Grant • Department of Defense (DOD) Ovarian Cancer Research Program Grants • NIH/NCI R03 • North Carolina Biotechnology Center (NCBC) Collaborative Funding Grant • American Cancer Society Research Scholar Grant My Laboratory (Past and Present): • Chunxiao Zhou, MD, PhD (Lab Manager) • Gynecologic Oncology Fellows 2007 – present • Hui Guo • Lu Zhang • Yajie Yin • Guangxu Xu • Collaborators: • Dhiren Thakker, PhD • Liza Makowski, PhD • Neil David Hayes, MD, PhD • Paola Gehrig, MD • Siobhan O’Connor, MD • Lisa Abaid, MD • Douglas Lee, PhD • Thomas Conrad, PhD • Larry Maxwell, MD

  34. The Becky Black Memorial Fund to Fight Endometrial Cancer

More Related